Search Results - "Kiechle, M."

Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort by Schrodi, S., Braun, M., Andrulat, A., Harbeck, N., Mahner, S., Kiechle, M., Klein, E., Schnelzer, A., Schindlbeck, C., Bauerfeind, I., Schubert-Fritschle, G., Nekljudova, V., Mayr, D., Weichert, W., Denkert, C., Loibl, S., Engel, J.

“…Guideline recommendations for the treatment of breast cancer with low hormone receptor (HR) expression (1%-9%) are ambiguous and several studies showed more…”
Get full text

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients by Harbeck, N, Schmitt, M, Meisner, C, Friedel, C, Untch, M, Schmidt, M, Sweep, C.G.J, Lisboa, B.W, Lux, M.P, Beck, T, Hasmüller, S, Kiechle, M, Jänicke, F, Thomssen, C

“…Abstract Aim Final 10-year analysis of the prospective randomised Chemo-N0 trial is presented. Based on the Chemo-N0 interim results and an European…”
Get full text

Bone marrow toxicity in patients with locally advanced cervical cancer undergoing multimodal treatment with VMAT/IMRT: are there dosimetric predictors for toxicity? by Hallqvist, D, Kormann, C, Pigorsch, S, Kiechle, M, Combs, S E, Habermehl, D

“…For women with locoregionally advanced cervical cancer, the standard of care treatment is the curatively intended chemoradiation therapy (CRT). A relationship…”
Get full text

Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial by Maurer, Tabea, Belau, M. H, Zyriax, B-C, Welsch, G, Jagemann, B, Chang-Claude, J, Daubmann, A, Buchholz, A, Glismann, K, Moeller, A, Sehouli, J, Woopen, H, Wimberger, P, Harter, P, Kaiser, S, Maass, N, Kiechle, M, Engler, T, Schmalfeldt, B, Schulz, H

“…Abstract Background In ovarian cancer frequently reported side effects are muscle wasting and malnutrition, leading to frailty, decreased health-related…”
Get full text

Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients by Pölcher, M., Rottmann, M., Brugger, S., Mahner, S., Dannecker, C., Kiechle, M., Brambs, C., Grab, D., Anthuber, C., von Koch, F., Schnelzer, A., Engel, J.

“…According to current treatment guidelines, comprehensive surgical staging procedures in endometrial cancer confined to the uterus depend on uterine risk…”
Get full text

Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1) by Berling-Ernst, A., Yahiaoui-Doktor, M., Kiechle, M., Engel, C., Lammert, J., Grill, S., Dukatz, R., Rhiem, K., Baumann, F. T., Bischoff, S. C., Erickson, N., Schmidt, T., Niederberger, U., Siniatchkin, M., Halle, M.

“…Physical activity (PA) helps prevention and aftercare of sporadic breast cancer (BC), cardiopulmonary fitness (CPF) being an age-independent predictor of…”
Get full text

Feasibility of quantitative sensory testing (QST) in clinical routine as a tool to evaluate chemotherapy-induced peripheral neuropathy (CIPN) amongst breast cancer patients treated with taxanes by Ioannou, I., Utpadel-Fischler, D., Tölle, T., Kiechle, M., Ettl, J.

Get full text

Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer by Scholz, Christoph, Andergassen, U., Hepp, P., Schindlbeck, C., Friedl, Thomas W. P., Harbeck, N., Kiechle, M., Sommer, H., Hauner, H., Friese, K., Rack, B., Janni, W.

“…Obese breast cancer patients have a higher risk of lymph node metastasis and a poorer prognosis compared to patients with normal weight. For obese women with…”
Get full text

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression by Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A., Erber, R., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., Thomssen, C., Kiechle, M., Jänicke, F., Wallwiener, D., Harbeck, N., Kuhn, W.

“…Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is…”
Get full text

Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes by Rottmann, Miriam, Burges, A., Mahner, S., Anthuber, C., Beck, T., Grab, D., Schnelzer, A., Kiechle, M., Mayr, D., Pölcher, M., Schubert-Fritschle, G., Engel, J.

“…Purpose The objective was to compare the prognostic factors and outcomes among primary ovarian cancer (OC), fallopian tube cancer (FC), and peritoneal cancer…”
Get full text

Trends in surgery and outcomes of squamous cell vulvar cancer patients over a 16-year period (1998–2013): a population-based analysis by Rottmann, M., Beck, T., Burges, A., Dannecker, C., Kiechle, M., Mayr, D., Schlesinger-Raab, A., Schubert-Fritschle, G., Engel, J.

“…Purpose The objective was to identify trends in surgery and the outcomes of squamous cell vulvar cancer in a population-based setting. Methods A total of 1113…”
Get full text

Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer by Dorn, J., Harbeck, N., Kates, R., Gkazepis, A., Scorilas, A., Soosaipillai, A., Diamandis, E., Kiechle, M., Schmalfeldt, B., Schmitt, M.

“…Primary tumor levels of serine proteases of the kallikrein-related peptidases (KLK) family as well as urokinase-type plasminogen activator (uPA) and its…”
Get full text

Retrospective analysis of utilization, compliance, tolerability and quality of life of breast cancer patients under complementary treatment (CAM) by Welz, B, Hapfelmeier, A, Kiechle, M, Paepke, D

Get full text

Time trends (2006–2015) of quality indicators in EUSOMA-certified breast centres by van Dam, P.A., Tomatis, M., Marotti, L., Heil, J., Mansel, R.E., Rosselli del Turco, M., van Dam, P.J., Casella, D., Bassani, L.G., Danei, M., Denk, A., Egle, D., Emons, G., Friedrichs, K., Harbeck, N., Kiechle, M., Kimmig, R., Koehler, U., Kuemmel, S., Maass, N., Mayr, C., Prové, A., Rageth, C., Regolo, L., Lorenz-Salehi, F., Sarlos, D., Singer, C., Sohn, C., Staelens, G., Tinterri, C., Audisio, R., Ponti, A., Badbanchi, F., Catalano, G., Cretella, E., Daniaux, M., Emons, A., van Eygen, K., Ettl, J., Gatzemeier, W., Kern, P., Schneeweiss, A., Stoeblen, F., Van As, A., Wuerstlein, R., Zanini, V.

“…The European Society of Breast Cancer Specialists (EUSOMA) has fostered a voluntary certification process for breast centres to establish minimum standards and…”
Get full text

RESCUE: Reaching for evidence-based chemotherapy use in endocrine sensitive breast cancer - A prospective non-interventional study on risk assessment by the endopredict test and long-term patient outcome in early luminal breast cancer by Ettl, J., Blohmer, J.-U., Denkert, C., Beier, L., Klein, E., Neuser, P., Keller, M., Untch, M., Wittenberg, M., Kiechle, M.

Get full text

Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years by Seifert-Klauss, V., Fillenberg, S., Schneider, H., Luppa, P., Mueller, D., Kiechle, M.

“…ABSTRACT Introduction Few longitudinal data about rates of bone loss in women in midlife exist. Fewer still with their reproductive states having been…”
Get full text

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study by Janni, W, Harbeck, N, Rack, B, Augustin, D, Jueckstock, J, Wischnik, A, Annecke, K, Scholz, C, Huober, J, Zwingers, T, Friedl, T W P, Kiechle, M

“…Background: Taxane-containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. This study compared efficacy and…”
Get full text

CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients by Windmüller, C, Zech, D, Avril, S, Boxberg, M, Dawidek, T, Schmalfeldt, B, Schmitt, M, Kiechle, M, Bronger, H

“…Intraabdominal tumor dissemination is a major hallmark of epithelial ovarian cancer (EOC), but the underlying mechanisms have not been fully elucidated. The…”
Get full text

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial by Gluz, O., Liedtke, C., Huober, J., Peyro-Saint-Paul, H., Kates, R.E., Kreipe, H.H., Hartmann, A., Pelz, E., Erber, R., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Thomssen, C., Jänicke, F., Kiechle, M., Wallwiener, D., Kuhn, W., Nitz, U., Harbeck, N.

“…Potential prognostic and predictive markers in early, intermediate-risk breast cancer (BC) include histological grade, Ki-67, genomic signatures, e.g. genomic…”
Get full text

Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies by Dorn, J, Bayani, J, Yousef, G M, Yang, F, Magdolen, V, Kiechle, M, Diamandis, E P, Schmitt, M

“…Kallikrein-related peptidases (KLK), which represent a major tissue-associated proteolytic system, stand for a rich source of biomarkers that may allow…”
Get more information